Perimenopause Beyond Estrogen: A More Individualized Approach to Hormone Therapy

For many women, the transition into menopause does not begin with a single, obvious symptom.

Instead, a patient in her 40s may walk into your office and tell you that she simply doesn’t feel like herself anymore.

She may be sleeping poorly. Her periods may have become unpredictable. She may feel more irritable or anxious than she used to. Her libido has changed. She is struggling with brain fog, fatigue, hot flashes, vaginal symptoms, or changes in body composition.

Sometimes she has already been told that her hormone levels are “normal.”

Other times, estrogen has already become the focus of the conversation.

But perimenopause is more complicated than a single hormone moving in a single direction.

Estrogen and progesterone production becomes increasingly variable as ovarian function changes, while androgen physiology, sleep, stress, metabolic health, medications, thyroid function, relationships, and numerous other factors can produce overlapping symptoms.

For prescribers, the opportunity isn’t simply to “replace hormones.”

It is to identify which symptoms are most likely related to the menopausal transition, determine which therapies are supported for those symptoms, and individualize treatment when the standard approach does not adequately fit the patient.

That distinction matters.

Personalized medicine does not necessarily mean prescribing more.

It means making the treatment fit the patient more precisely.

Perimenopause Is a Transition, Not a Hormone Deficiency Snapshot

One of the challenges of treating perimenopause is that ovarian function becomes increasingly variable before it eventually declines.

A woman can therefore experience meaningful menopausal symptoms while continuing to menstruate. Symptoms may fluctuate considerably from month to month, and a laboratory value obtained on one particular day may not tell the entire story of what she has experienced over the preceding several months.

This is why the clinical history remains so important.

Rather than asking only, “What is her estradiol level?” it may be more useful to ask:

• What has changed from her previous baseline?
• Are vasomotor symptoms present?
• Has sleep changed?
• Are cycles becoming irregular or unusually heavy?
• Has sexual desire changed?
• Are vaginal dryness, dyspareunia, or urinary symptoms emerging?
• What medications, medical conditions, psychosocial factors, or lifestyle changes could also be contributing?
• Which symptom is actually bothering her the most?

That last question can fundamentally change the treatment conversation.

A patient who says, “My hormones are off,” may primarily be asking for help with sleep.

Another may be most concerned about hot flashes.

Another may have few vasomotor symptoms but be distressed by vaginal discomfort or a significant change in sexual desire.

Those patients may require very different approaches.

Estrogen: Important, But the Clinical Goal Matters

Estrogen remains central to menopausal hormone therapy for good reason.

Hormone therapy remains the most effective treatment for vasomotor symptoms and can also provide important benefits for genitourinary symptoms and prevention of bone loss in appropriately selected patients. The benefits, risks, dose, route, and duration should be individualized to the patient and periodically reassessed.

But “estrogen therapy” itself is not a single treatment.

Prescribers have choices regarding route, dose, formulation, and whether the therapeutic goal is primarily local or systemic.

A patient whose primary concern is vaginal dryness or dyspareunia, for example, may need a very different strategy from someone experiencing disruptive hot flashes and night sweats.

Likewise, oral and transdermal systemic estrogen are not pharmacologically identical. Route can affect metabolism, tolerability, adherence, convenience, and aspects of the risk profile.

This is where individualized treatment begins to matter.

Not because every patient needs a custom-compounded medication, but because the therapeutic goal should determine the formulation rather than the formulation determining the therapy.

Progesterone: More Than Something Added to Estrogen

For women with an intact uterus receiving systemic estrogen, adequate progestogen exposure is important for endometrial protection.

But progesterone often becomes part of a broader clinical conversation during the menopausal transition.

Many perimenopausal patients present with sleep changes and altered bleeding patterns at the same time their cycles are becoming increasingly unpredictable. Depending on the patient’s indication, medical history, treatment goals, and overall hormone regimen, micronized progesterone may be one of the tools a clinician considers.

The important distinction is that progesterone should not simply be added because a patient has nonspecific symptoms or because an isolated laboratory value appears “low.”

The better question remains:

What are we trying to treat?

That keeps hormone therapy anchored to meaningful clinical outcomes rather than turning treatment into an attempt to make every laboratory value land within a predetermined “optimal” range.

Testosterone: An Important Conversation, But for the Right Patient

Testosterone may be one of the most misunderstood components of women’s hormone therapy.

Patients increasingly arrive asking whether low testosterone could explain fatigue, difficulty losing weight, low motivation, brain fog, diminished libido, or a general sense that they have lost some of their vitality.

The evidence requires considerably more precision.

The strongest evidence for testosterone therapy in women is for postmenopausal women with hypoactive sexual desire disorder (HSDD) after an appropriate biopsychosocial assessment. Current consensus guidance does not support testosterone as a general treatment for fatigue, cognition, body composition, mood, or overall wellbeing.

That assessment matters because sexual desire is influenced by far more than circulating testosterone.

Relationship factors, medications, depression and anxiety, sleep, pain, vaginal discomfort, estrogen deficiency, body image, medical illness, and life stress can all contribute.

A testosterone level by itself should not be used to diagnose HSDD.

When testosterone therapy is appropriate, the goal should be physiologic replacement rather than supraphysiologic exposure, with clinical response and signs of androgen excess monitored over time.

There is also a practical challenge for U.S. prescribers: there is no FDA-approved testosterone formulation specifically indicated for women.

That therapeutic gap is one reason testosterone frequently becomes a point of collaboration between prescribers and compounding pharmacists.

Where Compounding Actually Adds Value

The value of compounding is not that every menopausal patient needs compounded hormones.

Many do not.

FDA-approved estradiol and micronized progesterone products are available in multiple strengths and dosage forms. When one of those products appropriately meets the patient’s clinical needs, it may be the most straightforward option.

Professional guidance likewise recommends FDA-approved menopausal hormone therapies over routinely compounded alternatives when an appropriate approved product exists.

But patients do not always arrive in neat, commercially manufactured packages.

Compounding becomes useful when the treatment that makes sense clinically and the medication options that exist commercially do not quite match.

For example, a patient may need:

• A strength that is not commercially available
• Smaller dose adjustments during titration
• A different dosage form because of tolerability or adherence
• Removal of an excipient because of an allergy or intolerance
• A very-low-dose testosterone preparation when testosterone therapy has been appropriately selected
• A different application volume or dispensing system
• A formulation that better matches a local rather than systemic therapeutic goal
• A practical alternative when the existing formulation is creating enough friction that the patient is unlikely to use it consistently

Those may sound like small differences.

For the patient living with the treatment every day, they may be the difference between a theoretically appropriate prescription and one that actually fits her life.

That is the real benefit of compounding.

It provides another layer of flexibility when one-size-fits-most medicine reaches its limit.

Clinical Pearl #1: Treat the Patient, Not a Single Hormone Number

Patients understandably want objective answers.

They may arrive with saliva, serum, urine, or other hormone testing and expect the numbers to provide a roadmap for treatment.

Laboratory testing can certainly be useful when there is a clinically appropriate reason to obtain it. But menopausal hormone therapy should not become an exercise in adjusting medications until every hormone lands within a predetermined range.

Symptoms, medical history, indication, contraindications, treatment response, adverse effects, and ongoing monitoring remain central.

In perimenopause especially, fluctuating ovarian activity can complicate the interpretation of isolated measurements.

The data should support clinical decision-making.

They should not replace it.

Testing in Perimenopause: Know What It Can, and Can’t, Tell You

Patients increasingly arrive wanting more information about what is happening hormonally.

That curiosity is understandable.

Testing can sometimes provide useful supplemental information, but it is important to distinguish collecting more data from having data that should change treatment.

Major professional guidelines do not recommend routine adjunct hormone testing—including salivary testing—for determining the dose of menopausal hormone therapy. ACOG specifically notes that evidence supporting this approach is limited and raises concerns about the accuracy and precision of salivary sex-hormone measurements for this purpose.

That does not mean every hormone measurement is clinically meaningless.

It means the reason for ordering the test matters.

Custom Care offers at-home saliva testing through ZRT Laboratory. Depending on the selected panel, ZRT can measure hormones such as estradiol, progesterone, testosterone, DHEA-S, and cortisol, including multi-time-point cortisol collections.

If a patient and prescriber choose to use testing, we believe those results should be treated as one piece of the overall clinical picture—not a diagnosis, not a stand-alone explanation for nonspecific symptoms, and not an automatic dosing formula.

Cortisol deserves similar caution.

Although salivary cortisol has validated uses in specific endocrine evaluations, broad cortisol testing should not be used to diagnose the commonly marketed concept of “adrenal fatigue.” The Endocrine Society notes that adrenal fatigue is not an established medical diagnosis and that saliva or blood tests promoted for diagnosing it are not supported by good scientific evidence.

The practical question is therefore not:

“Can we measure another hormone?”

It is:

“Will this information meaningfully improve the clinical decision we are trying to make?”

Sometimes the answer may be yes.

Sometimes a different test will be more appropriate.

And sometimes the patient’s symptoms and history will tell the prescriber considerably more than another hormone panel.

That is the kind of testing conversation we want to help facilitate.

Clinical Pearl #2: Ask Which Symptom the Patient Would Most Like to Change

One of the simplest questions can also be one of the most useful:

“If we could improve one thing over the next three months, what would make the biggest difference in how you feel?”

The answer helps define the therapeutic target.

If the answer is hot flashes, the pathway may be relatively straightforward.

If it is painful intercourse, another approach may be more appropriate.

If it is low sexual desire, the evaluation expands.

If the answer is fatigue, brain fog, or weight gain, hormone therapy may or may not be the solution—and thyroid dysfunction, sleep disorders, nutritional issues, medication effects, metabolic disease, mood disorders, or other causes may deserve investigation.

Individualized medicine does not mean assuming every symptom is hormonal.

It means determining what is actually driving the patient’s problem before choosing the intervention.

Clinical Pearl #3: Route of Administration Is Part of the Prescription

Two prescriptions containing the same hormone are not necessarily equivalent simply because the milligram strength looks similar.

Oral, transdermal, vaginal, and buccal administration can produce different pharmacokinetic profiles and may serve different therapeutic goals.

This becomes particularly important when changing an existing regimen.

A patient switching from one route to another should not automatically be assumed to have received a 1:1 therapeutic equivalent.

Changing the route is a treatment change.

It deserves the same thought and follow-up as changing the dose.

This is also an area where collaboration with a compounding pharmacist can be especially useful.

Clinical Pearl #4: Give One Change Enough Time to Teach You Something

When estrogen, progesterone, testosterone, thyroid medication, supplements, and several lifestyle interventions are changed simultaneously, determining what helped—or what caused an unwanted effect—becomes extremely difficult.

When clinically feasible, deliberate titration allows both the patient and prescriber to learn from the response.

Define the goal.

Make an intentional change.

Establish an appropriate reassessment interval.

Then decide what comes next.

Personalized therapy does not necessarily mean more medications.

Often, it means more deliberate decision-making.

What a Good Compounding Pharmacy Should Actually Solve

A prescriber should not need to become a formulation expert just because a patient needs something outside the standard commercial toolbox.

You may know what you are trying to accomplish clinically but still have questions such as:

• What concentration would deliver a practical dose?
• Can the dose be adjusted without making the application volume unreasonable?
• Which dosage forms are feasible for this medication?
• Is there a way to remove an excipient the patient cannot tolerate?
• Would changing the route create a different dosing consideration?
• Can the medication be dispensed in a way that makes titration easier?
• What options exist when the patient understands the treatment plan but simply cannot use the current formulation consistently?

Those are formulation problems.

They should not become one more thing the prescriber’s office has to solve alone.

At Custom Care Compounding Pharmacy, our goal is to make those situations easier.

You do not need to call us already knowing the exact concentration, base, dispensing device, or formulation you want.

Bring us the clinical goal and the problem you are trying to solve.

Our pharmacy team can help identify feasible patient-specific formulation options, discuss practical dosing and administration considerations, and give the prescriber useful choices from which to make the final clinical decision.

And if you routinely treat a particular type of patient, that collaboration can become even more streamlined over time.

The benefit isn’t simply having access to another cream or capsule.

It is having another clinical resource available when the usual medication options don’t quite fit the person sitting in front of you.

The Bigger Opportunity in Perimenopause Care

Women are increasingly seeking help for symptoms they may have tolerated for years.

They are reading about hormone therapy. They are asking about testosterone. They are wondering whether changes in sleep, sexual function, temperature regulation, mood, or vaginal health are related to the menopausal transition.

And many are looking for clinicians willing to have a more comprehensive conversation.

Prescribers do not need to respond by prescribing more hormones.

They need a better framework for deciding when hormone therapy is appropriate, what problem it is intended to solve, and how to individualize treatment when the standard option does not adequately fit the patient.

Sometimes the best answer will be an FDA-approved therapy.

Sometimes it will be a nonhormonal intervention.

Sometimes additional evaluation will reveal that hormones were not the primary problem at all.

And sometimes the patient’s clinical needs will create a legitimate reason to customize the strength, route, dosage form, excipients, or administration of a medication.

That is where thoughtful collaboration between the patient, prescriber, and compounding pharmacist can become particularly valuable.

For Patients: Looking for More Information About Your Hormones?

If parts of this article sound familiar, the best first step is not necessarily deciding which hormone you need. It is understanding what has changed, which symptoms matter most to you, and what information would actually help your healthcare provider evaluate those symptoms.

Custom Care offers ZRT saliva hormone testing for patients and prescribers who decide that additional hormone information may be useful. We can explain what the available panels measure, how samples are collected, and the limitations of the testing so that the results can be discussed appropriately with your healthcare provider.

Testing is information—not a diagnosis—and hormone results should always be considered alongside your symptoms, medical history, and your prescriber’s clinical assessment.

Have a Patient Who Doesn’t Fit the Standard Option?

Some hormone patients are straightforward.

Others aren’t.

If you have a patient whose current regimen makes sense clinically but isn’t working practically—or you’re trying to determine the most appropriate strength, route, dosage form, application volume, or titration approach—you don’t have to solve the formulation piece on your own.

Our pharmacists are available to talk through the clinical goal with you and help identify patient-specific options for your consideration.

Sometimes the solution is compounded.

Sometimes an FDA-approved product already does exactly what the patient needs.

The goal is the same either way:

Find the treatment approach that best fits the individual patient.

Selected Clinical References

• The North American Menopause Society. The 2022 Hormone Therapy Position Statement of The North American Menopause Society.
• American College of Obstetricians and Gynecologists. Compounded Bioidentical Menopausal Hormone Therapy. Clinical Consensus No. 6.
• Davis SR, et al. Global Consensus Position Statement on the Use of Testosterone Therapy for Women.
• Endocrine Society. Adrenal Fatigue.
• ZRT Laboratory. Saliva Testing. Used here to describe ZRT’s available testing methodology and analytes, not as independent evidence of clinical utility.